Open AccessGNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)
Author(s) -
Terry D. Crawford,
James E. Audia,
S.F. Bellon,
Daniel J. Burdick,
Archana Bommi-Reddy,
Alexandre Côté,
Richard Cummings,
Martin Duplessis,
E. Megan Flynn,
Michael C. Hewitt,
Hon-Ren Huang,
Hariharan Jayaram,
Ying Jiang,
Shivangi Joshi,
James R. Kiefer,
J.M. Murray,
Christopher G. Nasveschuk,
Arianne Neiss,
Eneida Pardo,
F. Anthony Romero,
Péter Sandy,
Robert J. Sims,
Yong Tang,
Alexander M. Taylor,
Vickie Tsui,
Jian Wang,
Shumei Wang,
Yongyun Wang,
Zhijun Xu,
Laura E. Zawadzke,
Xiaoqin Zhu,
Brian K. Albrecht,
Steven Magnuson,
Andrea G. Cochran
Publication year - 2017
Publication title -
acs medicinal chemistry letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 66
ISSN - 1948-5875
DOI - 10.1021/acsmedchemlett.7b00132
Subject(s) - bromodomain , brd4 , epigenetics , drug candidate , drug discovery , computational biology , acetylation , chromosome , identification (biology) , biology , in vitro , bioinformatics , chemistry , genetics , gene , botany
The biological function of bromodomains, epigenetic readers of acetylated lysine residues, remains largely unknown. Herein we report our efforts to discover a potent and selective inhibitor of the bromodomain of cat eye syndrome chromosome region candidate 2 (CECR2). Screening of our internal medicinal chemistry collection led to the identification of a pyrrolopyridone chemical lead, and subsequent structure-based drug design led to a potent and selective CECR2 bromodomain inhibitor (GNE-886) suitable for use as an in vitro tool compound.